A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-05. Anything still debated is marked as such rather than presented as settled.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
in the manufacturing processes involved with an aircraft of this size, including titanium structures, chemical milling and the machining of integral panels." By the mid-1980s, PZL was planned to produce half of the Il-86, including the entire wing, and also to work on Il-86 developments (“Now we are preparing to manufacture units for the next model of the Il wide-body plane,” according to Belczak). From May 1977, the Polish factory manufactured entire empennages including tailplanes and the fin, all control surfaces, high-lift devices and engine pylons for the Il-86, representing "about 16 per cent of these aircraft." Amid labour and political unrest in Poland from 1980 onwards, the Voronezh factory was instructed to retain wing manufacture. After certification in 1980, annual Il-86 outputs were: 1980, 1; 1981, 0; 1982, 11; 1983, 12; 1984, 8; 1985, 9 (including the four for 8 ADON); 1986, 11; 1987, 10; 1988, 10; 1989, 9; 1990, 11 (including the three for export to China), 1991, 3. Of the 106 examples built, one never flew (being used for static tests) and three were exported. The five-year plan in force when the USSR ceased to exist called for 40 more aircraft to be manufactured by 1995, but the manufacturing facility closed in early 1992.
The HaloTag is a hydrolase, which has a genetically modified active site, which specifically binds the reactive chloroalkane linker and has an increased rate of ligand binding. The reaction that forms the bond between the protein tag and chloroalkane linker is fast and essentially irreversible under physiological conditions due to the terminal chlorine of the linker portion. In the aforementioned reaction, nucleophilic attack of the chloroalkane reactive linker causes displacement of the halogen with an amino acid residue, which results in the formation of a covalent alkyl-enzyme intermediate. This intermediate would then be hydrolyzed by an amino acid residue within the wild-type hydrolase. This would lead to regeneration of the enzyme following the reaction. However, in the modified haloalkane dehalogenase (HaloTag), the reaction intermediate cannot proceed through a subsequent reaction because it cannot be hydrolyzed due to the mutation in the enzyme. This causes the intermediate to persist as a stable covalent adduct with which there is no associated back reaction.
Per- and polyfluoroalkyl substances (PFAS or PFASs) are a group of synthetic organofluorine chemical compounds that have multiple fluorine atoms attached to an alkyl chain. Because of their high chemical and thermal stability, these compounds have long environmental lifetimes, and thus are commonly called "forever chemicals". The first PFAS, polychlorotrifluoroethylene, was synthesized in 1934. Their widespread use began in 1938 with the invention of Teflon (polytetrafluoroethylene), a fluoropolymer coating that resists heat, oil, stains, grease, and water. Since their inception, thousands of PFAS compounds have been created. They are used in a wide variety of products including waterproof fabric, yoga pants, carpets, shampoo, mobile phone screens, wall paint, furniture, adhesives, food packaging, firefighting foam, electrical insulation, and cosmetics. PFAS are often found in groundwater, wastewater and soil; wastewater treatment facilities and landfills have the highest levels of pollution. Furthermore, crop uptake of PFAS and bioaccumulation of PFAS into fish, livestock, and wildlife can act as potential routes of human exposure. In addition, areas near airports and air force bases are contaminated from the use of PFAS-containing firefighting foam.
Sources: en.wikipedia.org
== Manufacture == Almost all products rich in protein are suitable for the production of HVP. Today, it is made mainly from protein resources of vegetable origin, such as defatted oil seeds (soybean meal, grapeseed meal) and protein from maize (Corn gluten meal), wheat (gluten), pea, and rice. The process and the feedstock determines the organoleptic properties of the end product. Proteins consist of chains of amino acids joined through amide bonds. When subjected to hydrolysis (hydrolyzed), the protein is broken down into its component amino acids. In aHVP, hydrochloric acid is used for hydrolysis. The remaining acid is then neutralized by mixing with an alkali such as sodium hydroxide, which leaves behind table salt, which comprises up to 20% of the final product (acid-hydrolyzed vegetable protein, aHVP). In enzymatic HVP (eHVP), proteases are used to break down the proteins under a more neutral pH and lower temperatures. The amount of salt is greatly reduced. Because of the different processing conditions, the two types of HVP have different sensory profiles. aHVP is usually dark-brown in color and has a strong savory flavor, whereas eHVP usually is lighter in color and has a mild savory flavor.
=== Differential scanning calorimetry === Differential scanning calorimetry (DSC) is an analytical technique used to examine thermodynamic properties of molecules. It can study the thermal behavior of materials as they undergo physical and chemical changes during heat treatment. The parameters that are measured are referred to as the glass transition value (Tg) and melting temperature (Tm). These values are measured over time and are comparable between an inert reference sample and the analyte. Changes in the (Tm) and (Tg) values evaluate phase changes (solid, liquid-gel, liquid, etc.) in which an endothermic or exothermic process occurs. This technique is useful for monitoring the phase changes in phospholipids by providing information such as the amount of heat released or absorbed and time for phase transitions to occur, etc. DSC monitoring can occur at slow rates which is a disadvantage in monitoring fast phase transitions within phospholipids.
=== El Mencho successor named === On 18 March 2026, the Wall Street Journal reported that a US Citizen named Juan Carlos Valencia González ("El Pelón"), who also uses the aliases "El Pelon," "El Tricky Tres," "03," "El 3," and "Pelacas," was now the CJNG's new leader. On 6 April 2026, El Pais would confirm that Valencia Gonzalez, El Mencho's stepson through his marriage to Rosalinda González Valencia, had successfully worked his way through the power vacuum created by El Mencho's death to succeed him as head of the CJNG as well. However, at the time of his capture in April 2026, it was acknowledged that CJNG second-in-command Audias Flores Silva ("El Jardinero") was making an effort to lead the organization as well.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.